US5985654A - Recombinant poxvirus and streptococcal M protein vaccine - Google Patents

Recombinant poxvirus and streptococcal M protein vaccine Download PDF

Info

Publication number
US5985654A
US5985654A US08/205,348 US20534894A US5985654A US 5985654 A US5985654 A US 5985654A US 20534894 A US20534894 A US 20534894A US 5985654 A US5985654 A US 5985654A
Authority
US
United States
Prior art keywords
protein
virus
peptide
gene
fowlpox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/205,348
Other languages
English (en)
Inventor
Vincent A. Fischetti
Dennis E. Hruby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Oregon State University
Original Assignee
Rockefeller University
Oregon State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Oregon State University filed Critical Rockefeller University
Priority to US08/205,348 priority Critical patent/US5985654A/en
Application granted granted Critical
Publication of US5985654A publication Critical patent/US5985654A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/885—Streptococcus

Definitions

  • This invention is concerned with viruses such as the vaccinia and fowlpox viruses modified to contain the DNA sequence (gene) which will express in a mammalian host, including humans, a protein corresponding to the conserved, exposed region of the M6 protein. It is concerned also with the use of such modified products as vaccines to protect against streptococcal infection. Further, it is concerned with plasmids or other vectors carrying the said gene.
  • the M protein of group A streptococci is a fibrous dimer of helices arranged in a coiled coil extending about 50 nm from the surface of these organisms. It is a fibrillar molecule of which there exists more than 80 serological types M.
  • the protein renders the streptococcus resistant to nonimmune phagocytosis. It is the major virulence factor of streptococcal bacteria.
  • M6' protein a polypeptide corresponding to the C-terminal region of the M6 protein and encompassing the conserved exposed region of the M protein
  • the M6' polypeptide can be produced by modifying the genome of a virus of the family poxviridae such as the orthopoxvirus vaccinia or the avipoxvirus fowlpox to contain a genetically engineered gene ("the M6' gene") which, expresses the M6' protein.
  • the M6' protein can be administered to a mammal by administration to the mammal of a modified vaccinia or fowlpox virus containing a gene coding for the protein.
  • the present invention provides a protein capable of eliciting an immunoprotective response to streptococcal infection in a mammal, said protein comprises an amino acid sequence which is the same or substantially the same as the amino acid residue sequence in the conserved exposed region of the M6 protein.
  • the present invention also provides the M6' protein.
  • the present invention provides a gene coding for a protein capable of eliciting an immunoprotective response to a streptococcal infection in a mammal, wherein said protein comprises an amino acid sequence which is the same or substantially the same as an amino acid residue sequence in the conserved exposed region of the M6 protein.
  • the present invention also provides the M6' gene.
  • the present invention provides a plasmid containing a gene coding for a protein capable of eliciting an immunoprotective response to streptococcal infection in a mammal, wherein said protein comprises an amino acid sequence which is the same or substantially the same as an amino acid residue sequence in the conserved exposed region of the M6 protein.
  • the gene coding can be the M6' gene.
  • the present invention also provides a virus, preferably of the family poxviridae containing a gene coding for protein capable of eliciting an immunoprotective response to streptococcal infection in a mammal, wherein said protein comprises an amino acid sequence which is the same or substantially the same as an amino acid residue sequence in the conserved exposed region of the M6 protein.
  • Typical poxviruses include vaccinia and fowlpox; fowlpox is a preferred virus.
  • the gene the virus can contain is the M6' gene.
  • the present invention provides a virus containing a gene coding for a surface antigen or portion thereof of an prokaryote, said surface antigen or portion thereof being responsible for the virulence of said prokaryote.
  • Typical viruses include those of the family poxviridae, especially vaccinia and fowlpox; fowlpox being a preferred virus.
  • the surface antigen or portion thereof can be a protein capable of eliciting an immunoprotective response in a mammal, which comprises an amino acid sequence which is the same or substantially the same as an amino acid residue sequence in the conserved exposed region of the M6 protein.
  • the prokaryote can be a bacteria, especially streptococcus.
  • the gene the virus can contain is the M6' gene.
  • the present invention provides a vaccine comprising a pharmaceutically acceptable carrier and a virus containing a gene coding for a surface antigen or portion thereof of a prokaryote, said surface antigen or portion thereof being responsible for the virulence of said prokaryote; and, said virus is present in a sufficient amount for sufficient antigen or portion thereof to elicit a protective response to an infection caused by said prokaryote.
  • the surface antigen or portion thereof can be a protein capable of eliciting an immunoprotective response to streptococcal infection in a mammal, which comprises an amino acid sequence which is the same or substantially the same as an amino acid residue sequence in the conserved exposed region of the M6 protein; and the virus is present in a sufficient amount for sufficient protein to elicit a protective response to a streptococcal infection.
  • the prokaryote can be a bacteria, especially streptococcus.
  • typical viruses include those of the family poxviridae, especially vaccinia and fowlpox; fowlpox is preferred; and, the gene the virus can contain is the M6' gene.
  • the present invention provides a method of controlling prokaryotic infection in a mammal in need of such control which comprises administration to said mammal of a virus containing a gene coding for a surface antigen or portion thereof of a prokaryote, said surface antigen or portion thereof being responsible for the virulence of said prokaryote; and said virus being administered in a sufficient amount for sufficient antigen or portion thereof to elicit an antibody response to an infection caused by said prokaryote.
  • the surface antigen or portion thereof can be a protein capable of eliciting an immunoprotective response to streptococcal infection in a mammal, which comprises an amino acid sequence which is the same or substantially the same as an amino acid sequence in the conserved exposed region of the M6 protein; the virus being administered in a sufficient amount for the protein to elicit an antibody response sufficient to effect such control.
  • the prokaryote can be a bacteria, especially streptococcus.
  • typical viruses include those of the family poxviridae, especially vaccinia and fowlpox; fowlpox is preferred; and the gene the virus can contain is the M6' gene.
  • the present invention additionally provides a gene coding for a segment of a surface antigen or portion thereof of a prokaryote, said surface antigen being responsible for the virulence of said prokaryote; and, said segment of surface antigen or portion thereof is capable of eliciting an immunoprotective response to infection caused by said prokaryote in a mammal.
  • This is not a product of nature as the coding is for a segment of a surface antigen or portion thereof and not for the entire antigen.
  • the present invention likewise provides a plasmid containing a gene coding for a segment of a surface antigen or portion thereof of a prokaryote, said surface antigen being responsible for the virulence of said prokaryote; and, said gene coding not naturally being present in said plasmid.
  • the novel M6' gene of this invention in the novel plasmid pVV3:M6' has been deposited at the American Type Culture Collection. The deposit was of a sample of the pVV3:M6' plasmid in E. coli under the accession number 68003. The M6' gene is not naturally present in a plasmid of E. coli; or, "said gene coding (the M6' gene) not naturally being present in said plasmid (of E.
  • genes and plasmids within the scope hereof do not include products of nature or that which is already known, e.g., the M6 gene or the plasmid pVV3:M6.
  • the present invention provides a vaccine comprising a pharmaceutically acceptable carrier and a virus, preferably of the family poxviridae containing a gene coding for protein capable of eliciting an immunoprotective response to streptococcal infection in a mammal, wherein said protein comprises an amino acid sequence which is the same or substantially the same as an amino acid residue sequence in the conserved exposed region of the M6 protein; and said virus is present in a sufficient amount for sufficient protein to elicit a protective response to a streptococcal infection.
  • typical poxviruses include vaccinia and fowlpox; fowlpox is preferred; and, the gene the virus can contain is the M6' gene.
  • the present invention additionally provides a method of controlling streptococcal infection in a mammal in need of such control which comprises administration to said mammal of a virus of the family poxviridae containing a gene coding for protein capable of eliciting an immunoprotective response to streptococcal infection in a mammal, wherein said protein comprises an amino acid sequence which is the same or substantially the same as the amino acid residue sequence in the conserved exposed region of the M6 protein; said virus being administered in a sufficient amount for the protein to elicit an antibody response sufficient to effect such control.
  • typical poxviruses include vaccinia and fowlpox; fowlpox is preferred; and the gene the virus can contain is the M6' gene.
  • the term "the same or substantially the same” is used herein to describe the sequence of amino acids in proteins of this invention having the desirable activity because such proteins are either identical to the exposed conserved region of the M6 protein of a group A streptococci or so similar to the segment that they have the same activity. No undue experimentation is required to determine proteins which are so similar to the conserved exposed region of the M6 protein that they have the same activity as those which are the same as the region.
  • the skilled artisan, from reading this specification can prepare homologous polypeptides having the same activity and substantially the same sequence as the exposed conserved region of the M6 protein. For instance, the termini may be extended, e.g., to provide an anchor to bind the protein to a binder.
  • a protein with the same activity and a high degree of homology with the conserved exposed region might be synthesized more readily or be less expensive to prepare, and, this protein is considered within the scope of this invention.
  • the proteins of the present invention are not the entire M protein, but rather, have the same, or substantially the same amino acid sequence as the conserved, exposed region of the M6 protein of group A streptococci (or a portion thereof).
  • the polypeptides of this invention are not considered to be naturally occurring.
  • viruses are genetically modified to express these proteins.
  • synthesis of the proteins may be achieved by selective enzymatic or chemical cleavage from the M protein or by solid phase synthesis (see application of Fischetti mentioned under Related Applications).
  • proteins disclosed herein whether from the gene expression of a modified virus or from other synthesis are not products of nature because the proteins herein are not the entire M protein, but are the same or substantially the same as an amino acid sequence in only a portion of the M protein; said portion comprising the conserved exposed region of the M protein (or a portion thereof).
  • the proteins disclosed herein do not have the same characteristics and utility as any M protein or other naturally occurring protein, because the M protein cannot be utilized to protect against streptococcal infections because of species variability of the M protein from different strains of streptococci, whereas the proteins herein can be used to prepare vaccines affording protection which is not strain specific.
  • the proteins disclosed herein are not products of nature as they do not exist as distinct entities in nature and have never before been produced, and because no product of nature has the same properties as these proteins.
  • FIG. 1 shows the complete amino acid sequence of the M6 protein from strain D471 of a group A streptococcal culture from The Rockefeller University collection.
  • FIG. 2 illustrates a model of the complete M6 protein from strain D471 as it exists on the cell wall.
  • FIGS. 3 and 4 show the strategy utilized to produce products of this invention.
  • FIGS. 5 and 6 show the structure of the M6' protein and the M6' gene respectively.
  • FIG. 7 illustrates the location of the preferred conserved region peptides.
  • M protein the carboxy terminus
  • a segment of the M molecule is sheltered by the carbohydrate of the cell wall which is composed of a rhamnose backbone (open circle) and N-acetylglycosamine branches (closed circles).
  • the distal amino terminus of the M-protein is non-helical. Most of the M-molecule between the carbohydrate shelter and the non-helical region is exposed on the surface of the streptococcus.
  • FIG. 1 is the complete amino acid sequence of an M protein from a specific strain.
  • M proteins from other strains will have generally the same structural features and conformation, but the amino acid sequences will vary. The principal variations occur towards the amino terminal.
  • the molecules become more and more conserved towards the carboxy end. Thus homology within M molecules of different serotypes progressively increases at sites which are closer to the carboxy terminus and more proximal to the cell wall.
  • the conserved exposed region runs from about position 170 to position 299, and is more generally regarded as the region starting from Ile at position 210.
  • the conserved exposed region is preferably from about position 210 to approximately position 298.
  • the balance of the molecule is considered to be the conserved nonexposed region.
  • This invention is concerned with the conserved exposed region of the M-protein molecule.
  • the C repeat region of the M protein consists of highly conserved C repeat blocks, interspersed by spacer sequences which may be less highly conserved among different serotypes (see FIG. 7).
  • the highly conserved C1 and C2 repeat blocks are located adjacent to the cell wall, e.g., in type 6 streptococci.
  • FIG. 7 shows that the amino end of M protein is type specific (antigenically variable). Sequences in position 298-441 are generally cell associated. Within the conserved region occurs the C repeat region composed of the C1 Block, Spacer and C2 Block. The non-type-specific epitopes of M6 which are shared among other M protein serotypes to varying degrees are located here. Monoclonal and affinity-purified antipeptide antibodies which map to the B repeat region and pepsin site of M6 protein are shared among only 10% to 17% of more than 50 distinct serotypes. In contrast, antibodies which map to the adjacent C repeat region are shared among approximately 60% to 70% of the serotypes.
  • proteins of this invention can extend from the B5 repeat Block through the C repeat region and even from the B4 repeat Block to the carboxy terminus, for broad-based protection, it is preferred that the protein be the same or substantially similar to the conserved exposed region which runs from about position 170 to position 299, and it is even more preferred that the proteins be the same or substantially similar to the region that runs from about position 235 to position 299; i.e., completely contained within the highly conserved C repeat region.
  • numerals in parenthesis following the word peptide or protein or polypeptide, or the like, such as “peptide (240-260)" refer to a peptide or protein or polypeptide having an amino acid sequence which is the same or substantially the same as the sequence in the M6 protein spanning from the position of the first numeral to the position of the second numeral.
  • Absorption assays with antipeptide Fabs indicate that one Class I-specific mAb (10B6) maps to peptide (240-260), whereas the other Class I-specific mAb (10F5) maps to both peptide (240-260) and peptide (272-292).
  • antipeptide antibodies directed to peptide (240-260) and peptide (272-292) have substantial immunoreactivity with the extracted forms of several Class II M proteins on Western blot, although antipeptide antibodies to peptide (248-269) and peptide (256-277) may be Class I-specific.
  • a vaccine consisting of antigens corresponding to the C repeat region will protect against both Class I and Class II streptococci.
  • proteins which are the same or substantially the same as the sequence of the conserved exposed region of the M6 protein there is a preference for proteins which are the same as or are substantially similar to the sequence of the C repeat region or a portion thereof.
  • preferred proteins include polypeptide (216-235), polypeptide (248-269), polypeptide (275-284), polypeptide (240-260), polypeptide (256-277), and polypeptide (272-292) (see application of Fischetti mentioned under Related Applications).
  • Vaccines for use to protect against streptococcal infection have been proposed previously. These vaccines have been prepared from polypeptides from the hypervariable amino end of the molecule. They have enjoyed some success in providing type specific immunity against homologous serotypes. Their performance has been improved by incorporating several type specific determinants in the same multivalent vaccine. However, given the enormous array of existing M serotypes, this procedure is not an attractive one.
  • Group A streptococci are widespread human pathogens which are responsible for nasopharyngeal infections and impetigo. There are approximately 30 million cases of group A streptococcal infections each year in the United States alone. Despite the fact that streptococcal infection can be successfully treated with antibiotics, in the interim it often causes significant discomfort and loss in productivity. A small percentage of infected individuals afflicted with streptococcal infection develop a more serious illness such as rheumatic fever and glomerulonephritis. In developing countries, rheumatic fever is the leading cause of heart disease among children. Thus, there is a strong impetus to develop a safe and effective vaccine against group A streptococci.
  • streptococcal infections particularly pharengytis are generally limited to children.
  • the incidence of infection peaks at ages 6-8.
  • Adults are apparently more resistant to such infections, presumably because they have built up an immunity which is effective against most serotypes.
  • there may be an immunological response to streptococcal infections which produces antibodies which recognize epitopes on most, if not all streptococcal serotypes. It has been found that such epitopes are in the conserved region of the M protein which is not protected by its proximity to the cell wall, i.e., the conserved exposed region of the M protein.
  • amino acids in this region varies somewhat amongst serotypes, it generally runs from about amino acid 170 to position 299 on the M protein molecule, preferably from position 210 to 298 or 299 and even more preferably from about position 235 to about position 299.
  • Polypeptides or proteins from that region are capable of eliciting and do elicit a protective immune response when administered to a mammal in need of protection against streptococcal infection.
  • the mammalian body has several methods for protecting itself against infection by microorganisms.
  • One is the adaptive system in which the immune response to an invading organism results in the production of IgG antibodies which function by allowing opsonization and phagocytosis mediated by complement.
  • Another is the production or activation of IgA which is the predominant immunoglogulin of seromucous secretions such as saliva, tracheobronchial secretions, colostrum, milk and genito-urinary secretions.
  • IgG is also found in these secretions, but in a lesesr concentration.
  • Secretory IgA (sIgA) is a dimeric form of IgA protected from proteolysis by the secretory component.
  • IgA secretory IgA
  • One function of IgA is to prevent infective microorganisms from adhering, colonizing and invading the mucous tissue.
  • a presently preferred procedure for the practice of this invention involves, principally, the stimulation of the secretory immune system, particularly sIgA by intranasal or oral administration. There may be concomitant production of IgG, and both may contribute to the immunization. The invention will be described principally as applied to that procedure.
  • the polypeptides of the invention may also be used to stimulate IgA as the principal response by parenteral administration with concomitant production of low level IgA.
  • Vaccinia virus and fowlpox virus are members of the family poxviridae. Within the family poxviridae is the genus orthopoxvirus and the genus avipoxvirus, inter alia. There are more than 20 viruses in the family poxviridae including viruses responsible for smallpox, cowpox, fowlpox and mammalian diseases.
  • Fowlpox is in the genus Avipoxvirus, whereas vaccinia and smallpox are in the genus Orthopoxvirus.
  • the genus Avipoxvirus also includes canary pox, junco pox, pigeon pox, sparrow pox, starling pox and turkey pox. Characteristics of poxviruses include that the virons are large, brick-shaped (or ovoid in the case of the genus Parapoxvirus), approximately 300-450 by 170-260 nm in size, with an external envelope, a coat of tubular structures, and an internal structure made up of a DNA-containing core and one or two lateral bodies.
  • the genome consists of a single molecule of dsDNA with covalently closed ends ("hairpins”) with a size of 130-280 kbp.
  • the viruses have more than 100 proteins and several enzymes (including a DNA-dependent RNA polymerase, guanylmethyltransferase and poly (A) polymerase).
  • Initial transcription occurs within the virus core, leading to the synthesis of early proteins, some of which lead to uncoating of viral DNA allowing further transcription and DNA replication.
  • Replication and assembly occur in the cytoplasm in viroplasm ("viral factories"), and virions are released by budding (extracellular enveloped virions) or by cell destruction (intracellular enveloped virions).
  • viral factories viral factories
  • virions are released by budding (extracellular enveloped virions) or by cell destruction (intracellular enveloped virions).
  • This invention will be described principally as it relates to vaccinia and fowlpox as the vector for the gene expressing the conserved, exposed region of the M protein, but other vectors (viruses, especially members of poxviridae) can also be employed. Likewise, other genes for antigens of prokaryotes which are responsible for the virulence of said prokaryotes can also be employed.
  • Fowlpox is a preferred vector because about 1 in 100,000 persons exposed to vaccinia have an adverse reaction (e.g., encephalitis) whereas no such reaction is known to occur from exposure to fowlpox.
  • fowlpox virus is limited to avian species (see Taylor et al, "Protective immunity against avian influenza induced by fowlpox virus recombinant," Vaccine, vol. 6, December 1988, p. 504, incorporated herein by reference).
  • the fowlpox strain designated herein FP-1 is a Duvette Strain modified to be used as a vaccine in day old chickens; the strain is a commercial strain designated O DCEP 25/CE67/2309 October 1980 and is available from Institute Merieux, Inc.
  • Vaccinia and fowlpox are eukaryotic viruses which complete most phases of their respective reproductive cycles within the cytoplasm of a host cell. They are non-transforming viruses, i.e., the viral DNA does not become integrated in the host genome nor do any viral gene products cause transformation. The viruses are considered to be non-oncogenic. Vaccinia has been used for approximately 200 years in vaccines for inoculation against smallpox and the medical profession is well acquainted with the properties of the virus when used in a vaccine. Although inoculation with vaccinia is not without risk, the risks are on the whole well known, well defined, and the virus is considered relatively benign.
  • a modified virus preferably fowlpox virus or vaccinia virus, containing in their genome a genetically engineered gene expressing an antigen responsible for the virulence of a prokaryote, preferably the M6' gene or a gene expressing the conserved, exposed region of the M6 protein (M6' protein)
  • M6' protein a genetically engineered gene expressing an antigen responsible for the virulence of a prokaryote
  • M6' gene preferably the M6' gene or a gene expressing the conserved, exposed region of the M6 protein (M6' protein)
  • streptococcal infections such as streptococcal pharangytis.
  • FIGS. 3 and 4 The strategy used to assemble and isolate an appropriate virus recombinant containing the M6' gene and expressing the M6' protein is shown in FIGS. 3 and 4.
  • the production of the novel virus utilizes the known plasmid pVV3:M6 prepared as described by Hruby et al in Proc. Natl. Acad. Sci. USA Vol. 85 pp 5714-5717, August 1988 Microbiology (incorporated herein by reference) to produce the novel plasmid pVV3:M6' which is used to introduce the chimaeric M6' gene into the vaccinia or preferably the fowlpox virus genome to produce the recombinant virus VV:M6' or FPV:M6'.
  • novel vaccinia or fowlpox viruses containing the complete conserved region gene fragment of the M6 protein, i.e., containing the M6' gene for expressing a truncated M6 protein, herein identified as the M6' protein will confer significant protection from bacterial mucosal colonization when us ed as a prophylactic vaccine.
  • the novel vaccinia virus will be referred to herein as the VV:M6' virus
  • the novel fowlpox virus will be referred to herein as the FPV:M6' virus.
  • VV:M6' Virus Assembly
  • FIG. 3 shows the structure of the VV:M6' recombinant virus.
  • the top portion of the figure is a schematic representation of the major structural features of the protein encoded by the M6 open reading frame with conserved and variable regions among different M serotypes indicated. See Hollingshead et al, J. Biol. Chem. 261, 1677 (1986). The A, B, C, and D amino acid repeat blocks are indicated, as are the proline-glycine (Pro/Gly) rich region and the membrane anchor (M anchor). Using the indicated FokI site, the conserved 3'-half of the M6 gene was subdoned into a plasmid vector as described below.
  • the genomic structure of the VV:M6' recombinant is shown at the bottom of the figure.
  • the M6' insert is abutted to the constitutive 7.6 kDa viral thymidine kinase gene (bold arrows).
  • the approximate location of early (P 68 ) and late (P 65 ) transcriptional start sites are indicated, as well as the site used for termination of early transcripts (T 96 ).
  • the structure of the VV:M6' recombinant, the sequence of the junction regions, and the expression of the chimeric transcriptional unit was verified by DNA sequencing, Northern blot hybridization, and nuclease S1 mapping procedures.
  • the pVV:M6 plasmid was cut with FokI (cleaves at position 751 of the M6 sequence) and ClaI (cleaves at the 3' end of the insert).
  • FokI cleaves at position 751 of the M6 sequence
  • ClaI cleaves at the 3' end of the insert.
  • the fragment corresponding to the 3'-half of the M6 gene was isolated, the recessed ends filled in using the Klenow fragment of DNA polymerase I, and the blunt-ended fragment cloned into the SmaI site of M13mp 19 RF DNA.
  • a recombinant phage containing the insert in the correct orientation was identified by hybridization with a strand specific oligonucleotide probe.
  • Single-stranded DNA was prepared and used as a substrate for oligonucleotide-directed site-specific mutagenesis designed to introduce a G between positions 769 and 770 of the insert. This alteration, which was verified by Sanger dideoxynucleotide sequencing procedures, resulted in the Lys-209 codon of the M6 open reading frame being converted to anin-frame AGT codon.
  • the mutagenized insert (M6') was excised from the phage DNA using EcoRI and BamHI which cut at the 5' and 3' ends, respectively, of the M6' insert.
  • the structures of the M6' gene and the M6' protein are shown in FIGS. 5 and 6 using the standard symbols for the constituents.
  • the M6' protein includes the carboxy-terminal 234 amino acids of the M6 protein, from approximately amino acid 209 to the end of the molecule, and encompasses the conserved exposed region of the M6 protein.
  • VV:M6' Virus Efficacy
  • mice Groups of mice (Swiss CD1, Jackson Labs) were immunized intranasally with either the VV:M6' virus or the wild-type strain with a dose of 10 7 to 10 8 plaque forming units (PFU)/mouse. After four weeks, mice were challenged both intranasally and orally with M6 group A streptococci (strain S43/192 from the Rockefeller University Collection) which were made resistant to 200 ug/ml of streptomycin. All animals were housed 4-5/cage throughout the experiment. Preparation of the strain for challenge was as described by Bessen and Fischetti in Infect. Immun. 56,2666 (1988).
  • streptococci (6 ⁇ 10 6 or 1 ⁇ 10 7 colony forming units (CFU/mouse).
  • 20 ul of the streptococcal suspension were administered to each nostril and an additional 10 ul orally.
  • throats were swabbed (Calgiswab type 4, Spectrum) and cultured on blood agar plates containing 200 ug/ml of streptomycin to both discriminate and prevent competition between the growth of input streptococci and normal flora organisms. Cultures were grown overnight at 37° C. and scored for the presence of Beta-hemolytic streptococci.
  • mice which had died after challenge were autopsied and their spleens aseptically removed and cultured on streptomycin to both discriminate and prevent competition between the growth of input streptococci and normal flora organisms. Cultures were grown overnight at 37° C. and scored for the presence of Beta-hemolytic streptococci. Mice which had died after challenge were autopsied and their spleens aseptically removed and cultured on streptomycin-containing blood agar.
  • Table I shows the results of two separate experiments in which different groups of mice treated with either the wild type VV vaccine, or with VV:M6' vaccine and subsequently challenged.
  • the first group of 17 65% of animals immunized with the wild-type virus were colonized on day 1 after streptococcal challenge and remained essentially so or died during the duration of the experiment.
  • 100% of the mice were colonized on day 1, and more than half of them were dead by day 8.
  • In the VV:M6' immunized mice 0/20 (0%) in Experiment I and only 3/8 (38%) in Experiment II exhibited a positive throat culture on day 1 after challenge. Only 18% of all of the mice vaccinated with VV:M6' died during the experiments, whereas 48% of all of the mice vaccinated with wild type died. Spleen cultures taken from dead animals revealed Beta-hemolytic streptococci.
  • the insertion plasmid pVV3:M6' containing the M6' gene is produced as set forth in Example 1, and is inserted at a non-essential site in the genome of an attenuated fowlpox virus (FPV) (FP-1 strain).
  • the gene is inserted between two HincII sites of a 900 bp PvuII fragment of the FP-1 genome with subsequent deletion of approximately 30 bp.
  • the recombinant fowlpox virus, FPV:M6' is produced by methods described above in Example 1 for the vaccinia virus.
  • the structure of the FPV:M6' recombinant, the sequence of the junction regions, and the expression of the chimeric transcriptional unit are verified by DNA sequencing, Northern blot hybridization, and nuclease S1 mapping procedures.
  • the recombinant virus (FPV:M6') is grown, purified and then carefully analyzed to verify that the M6' insert is present, intact and actively transcribed in virus-infected cells.
  • the structures of the M6' gene and the M6' protein are shown in FIGS. 5 and 6 using standard symbols for constituents.
  • mice are immunized with either FPV:M6' virus or the wild-type strain and are thereafter challenged with M6 group A streptococci in accordance with the procedures set forth in Example 2. Likewise, confirmation of the presence of antibodies is as set forth in Example 2. The results obtained are substantially the same as set forth in Example 2.
  • Novel products which have thus far been described include the M6' gene, the plasmid pVV3:M6' containing the M6' gene, the M6' protein and the recombinant viruses VV:M6' and FPV:M6'. Without any admission of the need to do so, it is stated that a sample of the pVV3:M6' plasmid in E. coli has been deposited at the American Type Culture Collection under the accession number 68003; and, a sample of the recombinant vaccinia virus VV:M6' has also been deposited under the accession number ATCC VR 2242.
  • the M6' gene can be modified by addition or deletion of one or several codons, and the resulting modified M6' gene will, when incorporated into a virus such as a vaccinia virus or a fowlpox virus to give rise to the expression of modified M6' proteins having the same or substantially the same protective capacity for mammals against bacterial infection.
  • the vaccines of this invention will be prepared, typically for nasal, oral or parenteral administration, in accordance with standard techniques well known to those skilled in the pharmaceutical arts.
  • examples of such compositions include solid compositions for oral administration such as capsules, tablets, pills, and the like; liquid preparations for oral administration suspensions, syrups or elixers and preparations for parenteral administration such as sterile suspension or emulsions.
  • Many of these compositions can be adopted for nasal administration utilizing a type of packaging from which the composition can be delivered by the application of air, or other gas, pressure. They may also be manufactured in the form of sterile solid compositions which can be suspended in sterile water, physiological saline or glucose.
  • compositions will contain a sufficient amount of modified vaccinia virus and/or fowlpox virus to generate a protective response in the host or some other injectable, oral or nasal medium just prior to use.
  • the product can be provided in lyophilized form for reconstituting in isotonic aqueous, saline buffer.
  • Optimal dosages and regiments for a given mammalian host can be readily ascertained by those skilled in the art. Many factors well known to physicians and veterinarians will be taken into account principally including age and weight as well as route of administration. Booster techniques such as employed with other vaccines may be employed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US08/205,348 1989-06-21 1994-03-03 Recombinant poxvirus and streptococcal M protein vaccine Expired - Fee Related US5985654A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/205,348 US5985654A (en) 1989-06-21 1994-03-03 Recombinant poxvirus and streptococcal M protein vaccine

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36911889A 1989-06-21 1989-06-21
US54058690A 1990-06-19 1990-06-19
US96204892A 1992-10-16 1992-10-16
US8941593A 1993-07-09 1993-07-09
US08/205,348 US5985654A (en) 1989-06-21 1994-03-03 Recombinant poxvirus and streptococcal M protein vaccine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US8941593A Continuation 1989-06-21 1993-07-09

Publications (1)

Publication Number Publication Date
US5985654A true US5985654A (en) 1999-11-16

Family

ID=27004462

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/205,348 Expired - Fee Related US5985654A (en) 1989-06-21 1994-03-03 Recombinant poxvirus and streptococcal M protein vaccine

Country Status (10)

Country Link
US (1) US5985654A (es)
EP (1) EP0437604B1 (es)
JP (1) JP2577280B2 (es)
AT (1) ATE240396T1 (es)
AU (3) AU5948490A (es)
CA (1) CA2035039C (es)
DE (1) DE69034075T2 (es)
DK (1) DK0437604T3 (es)
ES (1) ES2199932T3 (es)
WO (1) WO1990015872A1 (es)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119133A1 (en) * 1997-10-31 2002-08-29 Vincent Fischetti Use of bacterial phage associated lysing enzymes for treating various illnesses
US20020127206A1 (en) * 1999-09-14 2002-09-12 Vincent Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US20030143245A1 (en) * 2001-10-26 2003-07-31 University Of Tennessee Research Corporation Multivalent streptococcal vaccine compositions and methods for use
US6685937B2 (en) 1997-10-31 2004-02-03 New Horizons Diagnostics Corp. Chewing gum containing phage associated lytic enzymes for treating streptococcal A infections
US6716433B1 (en) * 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
US6733749B2 (en) 1997-10-31 2004-05-11 New Horizons Diagnostics Corporation Throat lozenges for the treatment of Hemosphilus influenza
US6737079B2 (en) 1997-10-31 2004-05-18 New Horizons Diagnostics Corporation Bandage composition containing a phage associated lytic enzyme
US6752988B1 (en) 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US6893635B2 (en) 1997-10-31 2005-05-17 New Horizons Diagnostics Corp Therapeutic treatment of upper respiratory infections using a nasal spray
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US7687069B2 (en) 1997-10-31 2010-03-30 Vincent Fischetti Time release patch containing phage associated lytic enzymes for treating bacterial infections of the skin

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737521B1 (en) 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
SE9002213D0 (sv) * 1990-06-21 1990-06-21 Hightech Receptor Ab Albumin binding proteins
EP0672123A1 (en) * 1992-01-08 1995-09-20 The Rockefeller University Multifunctional surface protein of streptococci
JP3626181B2 (ja) * 1992-03-13 2005-03-02 ザ ロックフェラー ユニバーシティー グラム陽性菌の表面上のハイブリッド表面タンパク質の供給及び発現
WO1993021220A1 (en) * 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US9289485B2 (en) 2006-11-30 2016-03-22 Luiza Guilherme Guglielmi Therapeutic application of S. pyogenes C-terminal peptide
BRPI0604997A (pt) 2006-11-30 2007-05-22 Fundacao Zerbini vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784948A (en) * 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
WO1989009064A1 (en) * 1988-03-25 1989-10-05 The Rockefeller University Synthetic peptides from streptococcal m protein and vaccines prepared therefrom

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Hollingshead et al. (1986), The Journal of Biological Chemistry vol. 261, No. 4, pp. 1677 1686. *
Hollingshead et al. (1986), The Journal of Biological Chemistry vol. 261, No. 4, pp. 1677-1686.
Hruby et al. (Aug., 1988), PNAS, vol. 85, pp. 5714 5717. *
Hruby et al. (Aug., 1988), PNAS, vol. 85, pp. 5714-5717.
Rice et al. (1985), Journal of Virology, vol. 56, No. 1 pp. 227 239. *
Rice et al. (1985), Journal of Virology, vol. 56, No. 1 pp. 227-239.
Taylor et al. (Dec. 1988) Vaccine, vol. 6, pp. 497 503. *
Taylor et al. (Dec. 1988) Vaccine, vol. 6, pp. 497-503.

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716433B1 (en) * 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
US7402316B2 (en) 1997-09-12 2008-07-22 University Of Tennessee Research Foundation Group A streptococcal vaccines
US7255863B2 (en) 1997-09-12 2007-08-14 University Of Tennessee Research Foundation Group A streptococcal vaccines
US20050202037A1 (en) * 1997-09-12 2005-09-15 University Of Tennessee Research Foundation Group a streptococcal vaccines
US20050063988A1 (en) * 1997-09-12 2005-03-24 University Of Tennessee Research Foundation Group a streptococcal vaccines
US7014850B2 (en) 1997-10-31 2006-03-21 New Horizons Diagnostics Corp Nasal spray for treating streptococcal infections
US6893635B2 (en) 1997-10-31 2005-05-17 New Horizons Diagnostics Corp Therapeutic treatment of upper respiratory infections using a nasal spray
US7687069B2 (en) 1997-10-31 2010-03-30 Vincent Fischetti Time release patch containing phage associated lytic enzymes for treating bacterial infections of the skin
US6685937B2 (en) 1997-10-31 2004-02-03 New Horizons Diagnostics Corp. Chewing gum containing phage associated lytic enzymes for treating streptococcal A infections
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6733749B2 (en) 1997-10-31 2004-05-11 New Horizons Diagnostics Corporation Throat lozenges for the treatment of Hemosphilus influenza
US6737079B2 (en) 1997-10-31 2004-05-18 New Horizons Diagnostics Corporation Bandage composition containing a phage associated lytic enzyme
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US20020159987A1 (en) * 1997-10-31 2002-10-31 Vincent Fischetti Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US6875431B2 (en) 1997-10-31 2005-04-05 New Horizons Diagnostics Corp. Method for the treatment of bacterial eye infections
US6881403B2 (en) 1997-10-31 2005-04-19 New Horizons Diagnostic, Corp Tampon for the treatment of Streptococcus Group B infections of the vagina
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6899874B2 (en) 1997-10-31 2005-05-31 New Horizons Diagnostics Corporation Method for the treatment of bacterial vaginal infections
US20020127220A1 (en) * 1997-10-31 2002-09-12 Vincent Fiochetti Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract-
US6936244B2 (en) 1997-10-31 2005-08-30 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract
US20020146403A1 (en) * 1997-10-31 2002-10-10 Vincent Fischetti Method for the treatment of bacterial eye infections
US20020119133A1 (en) * 1997-10-31 2002-08-29 Vincent Fischetti Use of bacterial phage associated lysing enzymes for treating various illnesses
US7169408B2 (en) 1997-10-31 2007-01-30 New Horizons Diagnostics Corp. Bandage composition containing phage associated lytic enzymes useful for treating dermatological infections
US7141241B2 (en) 1997-10-31 2006-11-28 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating upper respiratory illnesses
US7063837B2 (en) 1999-09-14 2006-06-20 New Horizons Diagnostics Corp Syrup composition containing phage associated lytic enzymes
US20020127206A1 (en) * 1999-09-14 2002-09-12 Vincent Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6752988B1 (en) 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US20050136088A1 (en) * 2000-04-28 2005-06-23 New Horizons Diagnostics Corporation Use of bacterial phage associated lysing enzymes for treating various illnesses
US7270827B2 (en) 2001-10-26 2007-09-18 University Of Tennessee Research Foundation Multivalent streptococcal vaccine compositions and methods for use
US20030143245A1 (en) * 2001-10-26 2003-07-31 University Of Tennessee Research Corporation Multivalent streptococcal vaccine compositions and methods for use

Also Published As

Publication number Publication date
WO1990015872A1 (en) 1990-12-27
AU5948490A (en) 1991-01-08
DE69034075D1 (de) 2003-06-18
CA2035039A1 (en) 1990-12-22
DE69034075T2 (de) 2004-04-01
JPH03504336A (ja) 1991-09-26
JP2577280B2 (ja) 1997-01-29
AU6307494A (en) 1994-07-14
AU682344B2 (en) 1997-10-02
CA2035039C (en) 2000-02-01
EP0437604B1 (en) 2003-05-14
ATE240396T1 (de) 2003-05-15
ES2199932T3 (es) 2004-03-01
DK0437604T3 (da) 2003-09-15
EP0437604A1 (en) 1991-07-24
AU2855397A (en) 1997-10-02
EP0437604A4 (en) 1991-11-13

Similar Documents

Publication Publication Date Title
US5985654A (en) Recombinant poxvirus and streptococcal M protein vaccine
AU653387B2 (en) Antigen-presenting chimaeric protein
EA012037B1 (ru) Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
US5965124A (en) Replication-competent recombinant viral vaccines and method of producing same
JPH03502687A (ja) レスピラトリイ・シンシチアル・ウイルス：ワクチンおよび診断法
EP0584167A1 (en) Recombinant dna coding for signal peptide, selective interacting polypeptide and membrane anchoring sequence
US6737521B1 (en) Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
US7645455B2 (en) Chimeric lyssavirus nucleic acids and polypeptides
US5661006A (en) DNA encoding the Canine coronavirus spike protein
AU674311B2 (en) Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
JPH05509226A (ja) Ｅｈｖ―４糖蛋白質ワクチン
WO1988005817A1 (en) Expression of the p. falciparum circumsporozoite protein by yeast
EP0972840B1 (en) New attenuated myxoma recombinant virus and its use in the preparation of mixed vaccines against myxomatosis and rabbit hemorrhagic disease
US6096321A (en) ClpG subunit of CS31A protein capsule containing heterologous peptides
RU2215035C2 (ru) Рекомбинантный полиовирусный вектор (варианты), способ его получения (варианты), способ индукции иммунного ответа у индивидуума (варианты), способ получения белка (варианты), вакцинная композиция для терапии или профилактики инфекционных заболеваний (варианты)
JPH10509865A (ja) 細菌膜上で発現される呼吸器多核体ウイルスプロテインｇ
RU2745626C1 (ru) Способ создания живой вакцины против коронавирусной инфекции COVID-19 на основе пробиотического штамма Enterococcus faecium L3 и живая вакцина Enterococcus faecium L3-pentF-covid-19
US7238672B1 (en) Chimeric lyssavirus nucleic acids and polypeptides
KR0178110B1 (ko) 대장균에서 발현된 인간유래 한탄바이러스의 뉴클레오캡시드 단백질을 이용한 백신
CZ127394A3 (en) Replication-capable recombinant virus, process of obtaining thereof and vaccine composition
EP1721982B1 (en) Chimeric lyssavirus nucleic acids and polypeptides
Paoletti et al. A Modern Approach to Live Vaccines: Recombinant Poxviruses
Paoletti et al. Biotechnology: Potentials and Limitations, ed. S. Silver, pp. 155-164. Dahlem Konferenzen 1986. Berlin, Heidelberg, New York, Tokyo: Springer-Verlag.
Counc Outer membrane protein epitopes of Haemophilus influenzae; fusion protein expression in Escherichia coil: application to recombinant vaccine and antibody production, and in the production of reagents for diagnosis

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20111116